Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Seagen Inc

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Seagen Tukysa Maintains Survival Benefit, Delays Cancer Progression In The Brain In Breast Cancer Patients
Seagen Inc (NASDAQ: SGEN) has revealed new data from exploratory analyses from the HER2CLIMB trial of Tukysa (tucatinib) combined with trastuzumab &... 
Via Benzinga
Why This Investor Is Selling His Seagen Shares
Having fallen more than 22% over the last month, Seagen Inc (NASDAQ: SGEN) shares are now trading down about 15% year-to-date. With Seagen stock seemingly stuck in a downtrend,... 
Via Benzinga
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Investing $100,000 Into These 2 Stocks 10 Years Ago Would Have Made You a Millionaire Today
And doing so wouldn't have involved gambling with your portfolio, either. 
Via The Motley Fool
Where Seagen Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Seagen (NASDAQ: 
Via Benzinga
Expert Ratings For Seagen
Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the... 
Via Benzinga
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE: 
Via Benzinga
Notable Seagen Insider Trades $7.4M In Company Stock
Jean I Liu, Gc/EVP And Leg Afairs at Seagen (NASDAQ:SGEN), made a large buy and sell of company shares on November 1, according to a new SEC filing. What Happened: A Form 4 filing... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
CNBC's Final Trades: Seagen, Dollar Tree And This Pharma Major
On CNBC’s “Halftime Report Final Trades,&rd... 
Via Benzinga
Notable Seagen Insider Trades $7.4M In Company Stock
Todd E Simpson, Chief Financial Officer at Seagen (NASDAQ:SGEN), made a large buy and sell of company shares on October 29, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Seattle Genetics (SGEN) Q3 2021 Earnings Call Transcript
SGEN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Seattle Genetics's Earnings Outlook
Seattle Genetics (NASDAQ:SGEN) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Raymond James raised Alphabet Inc. (NASDAQ:GOOGL 
Via Benzinga
2 Stocks That Have Doubled the S&P 500's Returns Over the Past 5 Years and Could Still Go Higher
These companies just keep on growing. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings
Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings. Goldman rose 2.25% before the open helping to... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
A Bullish Sign Appears On Seagen's Chart
If history is any guide, there may be good fortune ahead for shares of Seagen(NASDAQ:SGEN). A so-called "golden cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
Why Genmab's Stock Is Trading Higher Today
Genmab A/S (NASDAQ:GMAB) shares are trading higher after the company, along with Seagen Inc. (NASDAQ: SGEN), announced the FDA has granted accelerated approval to... 
Via Benzinga
Exposures Product Safety
Why Seagen's Stock Is Trading Higher Today
Seagen (NASDAQ:SGEN) shares are trading higher after the company, along with Genmab A/S (NASDAQ: GMAB), announced the FDA has granted accelerated approval to TIVDAKTM... 
Via Benzinga
Exposures Product Safety
FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer
The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S’ (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The... 
Via Benzinga
Exposures Product Safety
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its... 
Via Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
A Look Into Seagen's Price Over Earnings
In the current market session, Seagen Inc. (NASDAQ:SGEN) is trading at $165.17, after a 0.24% drop. However, over the past month, the stock increased by 14.36%, and... 
Via Benzinga
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
Seagen Bets On China's ADC In $2.6B Cancer Deal
Seagen Inc (NASDAQ: SGEN) and RemeGen Co Ltd have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin... 
Via Benzinga
Seattle Genetics (SGEN) Q2 2021 Earnings Call Transcript
SGEN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.